Cardinals manager Mike Shildt says COVID-19 outbreak has resulted in ‘a few visits’ to emergency room
Multiple Cardinals have experienced symptoms from the coronavirus
Multiple Cardinals have experienced symptoms from the coronavirus
This episode features exclusive access with Omar Khan and Coach Tomlin at Pro Days, Pittsburgh native and scout Jim Ward, and a Kicking Clinic in…
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, as the competition in the…
A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, as the competition in the…
The drug industry officially has two new heavyweights. For the first time, Regeneron and Vertex have crossed the $100 billion market cap threshold. They join…
Gene editing’s therapeutic application has transitioned from hypothetical to reality, marked by the recent approval of a CRISPR-based therapy for sickle cell and beta thalassemia. |…
Newly named partner Anthony Philippakis and managing partner Krishna Yeshwant spoke with BioPharma Dive about biotech’s newfound optimism and their investing “North Star.”